Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Fiona Douglas.

Newcastle AuthorsTitleYearFull text
Dr Fiona Douglas
Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival after Radical Treatment for Localised Prostate Cancer2015
Dr Fiona Douglas
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers2014
Dr Fiona Douglas
Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndrome2014
Dr Fiona Douglas
DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers2014
Dr Fiona Douglas
Lymphocyte Telomere Length Is Long in BRCA1 and BRCA2 Mutation Carriers Regardless of Cancer-Affected Status2014
Dr Neil Rajan
Dr Piotr Pieniazek
Paul Hainsworth
Dr Fiona Douglas
Professor Ruth Plummer
et al.
Mesenteric cysts in Gorlin syndrome: a mimic of metastatic disease2014
Dr Fiona Douglas
Alexander Henderson
Penny Wilson
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: Results from the initial screening round of the IMPACT study2014
Dr Fiona Douglas
Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk2013
Dr Fiona Douglas
Alexander Henderson
Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer2013
Professor Kofi Oppong
Dr Paul Brennan
Dr Fiona Douglas
Richard Charnley
Pancreatic Cancer Screening - are we doing it right?2013
Dr Fiona Douglas
Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men2013
Dr Fiona Douglas
Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/22012
Dr Fiona Douglas
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers2012
Dr Fiona Douglas
Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers2012
Dr Fiona Douglas
Gene-gene interactions in breast cancer susceptibility2012
Dr Fiona Douglas
Is colorectal surveillance indicated in patients with PTEN mutations?2012
Dr Fiona Douglas
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers2011
Dr Fiona Douglas
Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA22011
Dr Fiona Douglas
Exploring the link between MORF4L1 and risk of breast cancer2011
Dr Fiona Douglas
Dr Chris Lord
Germline mutations in RAD51D confer susceptibility to ovarian cancer2011
Dr Fiona Douglas
Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer2011
Dr Fiona Douglas
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: Preliminary analysis of the results of the IMPACT study2011
Dr Elizabeth Jones
Dr Fiona Douglas
Dr Nicholas Bown
Wilms Tumor Incidence in Children With 2q Terminal Deletions: A Cohort Study2011
Dr Fiona Douglas
Dr Anne-Marie Gerdes
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population2010
Dr Fiona Douglas
Professor David Neal
The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine2010
Dr Fiona Douglas
Dr Stephen Ball
Tumour risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD2010
Dr John Beesley
Dr Anne-Marie Gerdes
Dr Fiona Douglas
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)2009
Dr Fiona Douglas
Dr Petros Perros
SDHB-associated renal oncocytoma suggests a broadening of the renal phenotype in hereditary paragangliomatosis2009
Dr Anne-Marie Gerdes
Dr Fiona Douglas
Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers2008
Dr Fiona Douglas
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: Validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics2008
Dr Stephen Ball
Dr Fiona Douglas
Professor Thomas Lennard
Familial endocrine disease: genetics, clinical presentation and management2006
Dr Stephen Ball
Dr Fiona Douglas
Professor Thomas Lennard
Familial endocrine disease: genetics, clinical presentation and management2006
Professor Sir John Burn
Dr Fiona Douglas
Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International society for gastrointestinal hereditary tumours collaborative study2006
Dr Rachel Davies
Dr Fiona Douglas
Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers2006
Dr Fiona Douglas
A randomised comparison of UK genetic risk counselling services for familial cancer: Psychosocial outcomes2004
Dr Fiona Douglas
Does cascading work in breast cancer families? A critical audit of BRCA1/BRCA2 mutation carriers and their at risk family members2004
Colin Wilson
Clive Griffith
Dr Jyotsna Shrimankar
Dr Fiona Douglas
Gynaecomastia, neurofibromatosis and breast cancer2004
Dr Fiona Douglas
Electronic patient records - implications for genetics2003
Dr Fiona Douglas
Dr Ann Curtis
Identification of a truncating mutation in the TES gene in a patient with familial ovarian cancer2003
Dr Fiona Douglas
Michelle Watson
Jamie Burn
A descriptive study of UK cancer genetics services: an emerging clinical response to the new genetics2001
Dr Fiona Douglas
Consent and Confidentiality: the issues that affect Clinical Genetics and the achievement of good practice in this context2001
Dr Fiona Douglas
Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma2001
Dr Fiona Douglas
Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma2001
Dr Fiona Douglas
Mutations in the mitochondrial complex II subunit SDHB cause susceptibility to familial phaeochromocytoma and paraganglioma2001
Dr Ujjal Mallick
Dr John Fenwick
Dr Robert James
Dr Sarah Johnson
Professor Pat Kendall-Taylor
et al.
Northern cancer network guidelines for management of thyroid cancer2000
Dr Ujjal Mallick
Dr Helen Lucraft
George Proud
Dr Petros Perros
Dr John Fenwick
et al.
Optimizing the management of differentiated thyroid cancer.2000
Dr Fiona Douglas
Dr Sally Lynch
The accuracy of diagnoses as reported in families with cancer: a retrospective study1999
Dr Fiona Douglas
Dr Sally Lynch
The accuracy of diagnoses as reported in families with cancer: A retrospective study1999